WO1997041222A1 - ALLELES D'EPISSAGE DU RECEPTEUR P2x4 HUMAIN - Google Patents

ALLELES D'EPISSAGE DU RECEPTEUR P2x4 HUMAIN Download PDF

Info

Publication number
WO1997041222A1
WO1997041222A1 PCT/GB1996/001034 GB9601034W WO9741222A1 WO 1997041222 A1 WO1997041222 A1 WO 1997041222A1 GB 9601034 W GB9601034 W GB 9601034W WO 9741222 A1 WO9741222 A1 WO 9741222A1
Authority
WO
WIPO (PCT)
Prior art keywords
polypeptide
seq
polynucleotide
amino acid
acid sequence
Prior art date
Application number
PCT/GB1996/001034
Other languages
English (en)
Inventor
Mark Thomas Mchale
William Jeffrey Tomlinson
Craig David Livingstone
David James Carpenter
Li Yi
Original Assignee
Smithkline Beecham P.L.C.
Human Genome Sciences Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham P.L.C., Human Genome Sciences Inc. filed Critical Smithkline Beecham P.L.C.
Priority to JP53864697A priority Critical patent/JP2001521372A/ja
Priority to AU55068/96A priority patent/AU5506896A/en
Priority to PCT/GB1996/001034 priority patent/WO1997041222A1/fr
Priority to EP96912122A priority patent/EP0907729A1/fr
Publication of WO1997041222A1 publication Critical patent/WO1997041222A1/fr

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Definitions

  • This invention relates to newly identified polynucleotides, polypeptides encoded by such polynucleotides, the use of such polynucleotides and polypeptides, as well as the production of such polynucleotides and polypeptides. More particularly, the polypeptide of the present invention is a novel human brain P2 X receptor and its splice variants. The invention also relates to modulating the action of such polypeptides and to the identification of drugs which modulate the actions of such polypeptides.
  • the P2 purinoceptors have ATP as ligand.
  • the P2 ⁇ subtype form a directly gated ion channel.
  • Rat adult brain (Seguela, P. et. al., 1996, J. Neuroscience 16: 448-455), rat vas deferens (Valera, S. et. al., 1994, Nature 371: 516-519 and WO95/33048), human urinary bladder (WO95/33048), rat PC12 (Brake, A. J. et.
  • polypeptide which is a human brain P2 X receptor polypeptide:
  • SEQ ID NO 3 or a fragment, analogue or derivative thereof.
  • polypeptide(s) will be used to refer to the human brain P2 X receptor and it fragments analogues and derivatives.
  • the polypeptide having the deduced amino acid sequence of SEQ ID NO 3 is referred to herein as the P2 X - 1 receptor, SEQ ID NO 4 as the the P2 ⁇ -2 receptor, and the human brain P2 X receptor polypeptide characterised by the deduced amino acid sequence of SEQ LD NO 5 as the P2 ⁇ -3 receptor.
  • polynucleotides (DNA or RNA) which encode such polypeptides.
  • a polynucleotide which encodes a polypeptide of SEQ ID NO 3 or 4 or characterised by the deduced amino acid sequence of SEQ ID NO 5
  • the invention provides a polynucleotide having the DNA sequence given in SEQ ID NO 1 or 2.
  • mRNA encoding the P2 ⁇ -1 receptor was isolated from human brain frontal cortex mRNA.
  • the predicted amino acid sequence of the P2 ⁇ -1 receptor has 388 amino acids and is 87, 51, 47 and 47% identical with rat adult brain (Seguela, P. et. al., 1996, J. Neuroscience 16: 448-455), rat vas deferens (Valera, S. et. al., 1994, Nature 3J71: 516- 519), rat PC12 (Brake, A. J. et.
  • mRNA encoding the P2 ⁇ -2 receptor was isolated from human brain frontal cortex.
  • the P2 x -2 receptor is distinguished from P2 X - 1 by the insertion of 48 base pairs between nucleotides 135 and 136 from the ATG start codon.
  • the P2 ⁇ -2 mRNA encodes an inframe insertion of 16 amino acids between amino acid residues 45 and 46.
  • the new insert sequence is [CYHLHLAEVEMESPRR]. This suggests the expression of a human brain P2 x -2 receptor isoform with a calculated molecular mass of 43.37 Kda.
  • EST Genbank database Accession Number R60722 was isolated from a 73 day postnatal female whole brain cDNA library. The encoded amino acid residues of EST (R60722), share a high degree of identity with the human brain P2 ⁇ -1 (residues 1 ⁇ 233). Residues 46 to 175 are deleted from the EST (R60722) as compared with the human brain P2x ⁇ l receptor. Further examination of this P2 ⁇ splice variant reveal the following points of interest:
  • the EST (R60722) deletion removes a substantial part of the extracellular region, including 6 of the 10 conserved cysteine residues involved in maintaining structural integrity of a putative ATP binding site.
  • a large extracellular region The human brain P2 ⁇ -1 receptor contains a large extracellular region spanning ⁇ 270 amino acids. This region contains 10 conserved cysteines, present in all P2 X receptors, suggesting an important role in maintaining the three-dimensional structure of the receptor. The extracellular region contains 12 conserved glycines and 7 conserved lysine residues. These residues are commonly associated with nucleotide-binding sites (Traut, T. W., 1994, Eur. J. Biochem. 222, 9-19). Mutational data [Buell, G. et al EMBO, J. 15 55-62 (1996)] and the clustering of these residues supports the view that the extracellular region is involved in binding.
  • the human brain P2 X sequences of this invention contain a sequence similar to the Walker type-A ATP-binding motif (Walker, J. et. al.,
  • the human brain P2 X sequences of this invention contain an 8 amino acid sequence in the region preceeding and overlapping the second hydrophobic potential transmembrane domain.
  • the human brain P2 X sequence, [TMINIGSG] closely resembles a motif which is conserved among all P2 ⁇ receptors. Further, this so-called H5 pore region is conserved in all voltage-gated potassium channels, inward rectifier potassium channels, and cyclic-nucleotide-gated cation channels (Ashford, M. L. et. al., 1994, Nature 370: 456-459).
  • the polynucleotide of the present invention may be in the form of RNA or in the form of DNA, which DNA includes cDNA, genomic DNA, and synthetic DNA.
  • the DNA may be double-stranded or single-stranded, and if single stranded may be the coding strand or non-coding (anti-sense) strand.
  • the coding sequence which encodes the mature polypeptide may be identical to the coding sequence shown in SEQ ID NO 1 or 2 or may be a different coding sequence which coding sequence, as a result of the redundancy or degeneracy of the genetic code, encodes the same mature polypeptide as the DNA of SEQ ID NO 1 or 2.
  • the polynucleotide which encodes for the mature polypeptide of the invention may include: only the coding sequence for the mature polypeptide; the coding sequence for the mature polypeptide and additional coding sequence such as a leader or secretory sequence or a proprotein sequence; the coding sequence for the mature polypeptide (and optionally additional coding sequence) and non-coding sequence, such as introns or non- coding sequence 5' and/or 3' of the coding sequence for the mature polypeptide.
  • the term "polynucleotide encoding a polypeptide” encompasses a polynucleotide which includes only coding sequence for the polypeptide as well as a polynucleotide which includes additional coding and/or non-coding sequence.
  • the present invention further relates to variants of the hereinabove described polynucleotides which encode for fragments, analogs and derivatives of the mature polypeptide.
  • the variant of the polynucleotide may be a naturally occurring allelic variant of the polynucleotide or a non-naturally occurring variant of the polynucleotide.
  • the present invention includes polynucleotides encoding the same mature polypeptide as well as variants of such polynucleotides which variants encode for a fragment, derivative or analog of the mature polypeptide.
  • Such nucleotide variants include deletion variants, substitution variants and addition or insertion variants.
  • the polynucleotide may have a coding sequence which is a naturally occurring allelic variant of the coding sequence shown in SEQ ID NO 1 or 2.
  • an allelic variant is an alternate form of a polynucleotide sequence which may have a substitution, deletion or addition of one or more nucleotides, which does not substantially alter the function of the encoded polypeptide.
  • the present invention also includes polynucleotides, wherein the coding sequence for the mature polypeptide may be fused in the same reading frame to a polynucleotide sequence which aids in expression and secretion of a polypeptide from a host cell, for example, a leader sequence which functions as a secretory sequence for controlling transport of a polypeptide from the cell.
  • the polypeptide having a leader sequence is a preprotein and may have the leader sequence cleaved by the host cell to form the mature form of the polypeptide.
  • the polynucleotides may also encode for a proprotein which is the mature protein plus additional 5' amino acid residues.
  • a mature protein having a prosequence is a proprotein and is an inactive form of the protein.
  • the polynucleotide of the present invention may encode for a mature protein, or for a protein having a prosequence or for a protein having both a prosequence and a presequence (leader sequence).
  • the polynucleotides of the present invention may also have the coding sequence fused in frame to a marker sequence which allows for purification of the polypeptide of the present invention.
  • the marker sequence may be a hexa-his ⁇ dine tag supplied by a pQE-9 vector to provide for purification of the mature polypeptide fused to the marker in the case of a bacterial host, or, for example, the marker sequence may be a hemagglutinin (HA) tag when a mammalian host, e.g. COS-7 cells, is used.
  • the HA tag corresponds to an epitope derived from the influenza hemagglutinin protein (Wilson, I., et al., Cell, 37:767 (1984)).
  • the present invention further relates to polynucleotides which hybridize to the hereinabove-described sequences under stringent conditions to the hereinabove-described polynucleotides.
  • stringent conditions means hybridization will occur only if there is at least 95% and preferably at least 97% identity between the sequences.
  • the polynucleotides which hybridize to the hereinabove described polynucleotides in a preferred embodiment encode polypeptides which retain substantially the same biological function or activity as the mature polypeptide of the invention.
  • the polypeptide of the present invention may be a recombinant polypeptide, a natural polypeptide or a synthetic polypeptide, preferably a recombinant polypeptide.
  • fragment when referring to the mature polypeptide of the invention, means a polypeptide which retains essentially the same biological function or activity as such polypeptide.
  • an analogue includes a proprotein which can be activated by cleavage of the proprotein portion to produce an active mature polypeptide.
  • the fragment, derivative or analogue of the mature polypeptide of the invention may be (i) one in which one or more of the amino acid residues are substituted with a conserved or non-conserved amino acid residue (preferably a conserved amino acid residue) and such substituted amino acid residue may or may not be one encoded by the genetic code, or (ii) one in which one or more of the amino acid residues includes a substituent group, or (iii) one in which the mature polypeptide is fused with another compound, such as a compound to increase the half-life of the polypeptide (for example, polyethylene glycol), or (iv) one in which the additional amino acids are fused to the mature polypeptide, such as a leader or secretory sequence or a sequence which is employed for purification of the mature polypeptide or a proprotein sequence.
  • a conserved or non-conserved amino acid residue preferably a conserved amino acid residue
  • substituted amino acid residue may or may not be one encoded by the genetic code
  • polypeptides and polynucleotides of the present invention are preferably provided in an isolated form, and preferably are purified to homogeneity.
  • isolated means that the material is removed from its original environment (e.g., the natural environment if it is naturally occurring).
  • a naturally-occurring polynucleotide or polypeptide present in a living animal is not isolated, but the same polynucleotide or polypeptide, separated from some or all of the coexisting materials in the natural system, is isolated.
  • Such polynucleotides could be part of a vector and/or such polynucleotides or polypeptides could be pan of a composition, and still be isolated in that such vector or composition is not part of its natural environment.
  • the present invention also relates to vectors which include polynucleotides of the present invention, host cells which are genetically engineered with vectors of the invention and the production of polypeptides of the invention by recombinant techniques.
  • a process for producing the polypeptide of the invention by recombinant techniques by expresssing a polynucleotide encoding said polypeptide in a host and recovering the expressed product.
  • the polypeptides of the invention can be synthetically produced by conventional peptide synthesizers.
  • Host cells are genetically engineered (transduced or transformed or transfected) with the vectors of this invention which may be, for example, a cloning vector or an expression vector.
  • the vector may be, for example, in the form of a plasmid, a viral particle, a phage, etc.
  • the engineered host cells can be cultured in conventional nutrient media modified as appropriate for activating promoters, selecting transformants or amplifying the human P2x receptor genes.
  • the culture conditions such as temperature, pH and the like, are those previously used with the host cell selected for expression, and will be apparent to the ordinarily skilled artisan.
  • the polynucleotides of the present invention may be employed for producing polypeptides by recombinant techniques.
  • the polynucleotide may be included in any one of a variety of expression vectors for expressing a polypeptide.
  • Such vectors include chromosomal, nonchromosomal and synthetic DNA sequences, e.g., derivatives of SV40; bacterial plasmids; phage DNA; baculovirus; yeast plasmids; vectors derived from combinations of plasmids and phage DNA, viral DNA such as vaccinia, adenovirus, fowl pox virus, and pseudorabies.
  • any other vector may be used as long as it is replicable and viable in the host.
  • the appropriate DNA sequence may be inserted into the vector by a variety of procedures. In general, the DNA sequence is inserted into an appropriate restriction endonuclease site(s) by procedures known in the art. Such procedures and others are deemed to be within the scope of those skilled in the art.
  • the DNA sequence in the expression vector is operatively linked to an appropriate expression control sequence(s) (promoter) to direct mRNA synthesis. As representative examples of such promoters, there may be mentioned: LTR or SV40 promoter, the E. coli. lac or irrj, the phage lambda PL promoter and other promoters known to control expression of genes in prokaryotic or eukaryotic cells or their viruses.
  • the expression vector also contains a ribosome binding site for translation initiation and a transcription terminator.
  • the vector may also include appropriate sequences for amplifying expression.
  • the expression vectors preferably contain one or more selectable marker genes to provide a phenotypic trait for selection of transformed host cells such as dihydrofolate reductase or neomycin resistance for eukaryotic cell culture, or such as tetracycline or ampicillin resistance in E. coli.
  • the vector containing the appropriate DNA sequence as hereinabove described, as well as an appropriate promoter or control sequence, may be employed to transform an appropriate host to permit the host to express the protein.
  • appropriate hosts there may be mentioned: bacterial cells, such as E. coli. Streptomvces. Salmonella typhimurium: fungal cells, such as yeast; insect cells such as Drosophila and SJ2; animal cells such as CHO, COS or Bowes melanoma; plant cells, etc.
  • the selection of an appropriate host is deemed to be within the scope of those skilled in the art from the teachings herein. More particularly, the present invention also includes recombinant constructs comprising one or more of the sequences as broadly described above.
  • the constructs comprise a vector, such as a plasmid or viral vector, into which a sequence of the invention has been inserted, in a forward or reverse orientation.
  • the construct further comprises regulatory sequences, including, for example, a promoter, operably linked to the sequence.
  • regulatory sequences including, for example, a promoter, operably linked to the sequence.
  • Bacterial pQE70, pQE60, pQE-9 (Qiagen), pbs, pDIO, phagescript, psiX174, pbluescript SK, pbsks, pNH8A, pNH16a, pNH18A, pNH46A (Stratagene); ptrc99a, pKK223-3, pKK233-3, pDR540, pRIT5 (Pharmacia).
  • Eukaryotic pWLNEO, pSV2CAT, pOG44, pXTl, pSG (Stratagene) pSVK3, pBPV, pMSG, pSVL (Pharmacia).
  • any other plasmid or vector may be used as long as they are replicable and viable in the host.
  • Promoter regions can be selected from any desired gene using CAT (chloramphenicol transferase) vectors or other vectors with selectable markers.
  • Two appropriate vectors are PKK232-8 and PCM7.
  • Particular named bacterial promoters include lad, lacZ, T3, T7, gpt, lambda PR, PL and trp.
  • Eukaryotic promoters include CMV immediate early, HSV thymidine kinase, early and late SV40, LTRs from retrovirus, and mouse metallothionein-I. Selection of the appropriate vector and promoter is well within the level of ordinary skill in the art.
  • the present invention relates to host cells containing the above-described constructs.
  • the host cell can be a higher eukaryotic cell, such as a mammalian cell, or a lower eukaryotic cell, such as a yeast cell, or the host cell can be a prokaryotic cell, such as a bacterial cell.
  • Introduction of the construct into the host cell can be effected by calcium phosphate transfection, DEAE-Dextran mediated transfection, or electroporation. (Davis, L., Dibner, M., Battey, I., Basic Methods in Molecular Biology, (1986)).
  • the constructs in host cells can be used in a conventional manner to produce the gene product encoded by the recombinant sequence.
  • the polypeptides of the invention can be synthetically produced by conventional peptide synthesizers. Mature proteins can be expressed in mammalian cells, yeast, bacteria, or other cells under the control of appropriate promoters. Cell-free translation systems can also be employed to produce such proteins using RNAs derived from the DNA constructs of the present invention. Appropriate cloning and expression vectors for use with prokaryotic and eukaryotic hosts are described by Sambrook, et al., Molecular Cloning: A Laboratory Manual, Second Edition, Cold Spring Harbor, N.Y., (1989), the disclosure of which is hereby incorporated by reference.
  • Enhancers are cis-acting elements of DNA, usually about from 10 to 300 bp that act on a promoter to increase its transcription. Examples including the SV40 enhancer on the late side of the replication origin bp 100 to 270, a cytomegalovims early promoter enhancer, the polyoma enhancer on the late side of the replication origin, and adenovirus enhancers.
  • recombinant expression vectors will include origins of replication and selectable markers permitting transformation of the host cell, e.g., the ampicillin resistance gene of E. coli and S. cerevisiae TRP1 gene, and a promoter derived from a highly-expressed gene to direct transcription of a downstream structural sequence.
  • promoters can be derived from operons encoding glycolytic enzymes such as 3- phosphoglycerate kinase (PGK), _-factor, acid phosphatase, or heat shock proteins, among others.
  • PGK 3- phosphoglycerate kinase
  • the heterologous structural sequence is assembled in appropriate phase with translation initiation and termination sequences, and preferably, a leader sequence capable of directing secretion of translated protein into the periplasmic space or extracellular medium.
  • the heterologous sequence can encode a fusion protein including an N-terminal identification peptide imparting desired characteristics, e.g., stabilization or simplified purification of expressed recombinant product.
  • Useful expression vectors for bacterial use are constructed by inserting a structural DNA sequence encoding a desired protein together with suitable translation initiation and termination signals in operable reading phase with a functional promoter.
  • the vector will comprise one or more phenotypic selectable markers and an origin of replication to ensure maintenance of the vector and to, if desirable, provide amplification within the host.
  • Suitable prokaryotic hosts for transformation include E. coli. Bacillus subtilis. Salmonella typhimurium and various species within the genera Pseudomonas, Streptomyces, and Staphylococcus, although others may also be employed as a matter of choice.
  • useful expression vectors for bacterial use can comprise a selectable marker and bacterial origin of replication derived from commercially available plasmids comprising genetic elements of the well known cloning vector pBR322 (ATCC 37017).
  • cloning vector pBR322 ATCC 37017
  • Such commercial vectors include, for example, pKK223-3 (Pharmacia Fine Chemicals, Uppsala, Sweden) and GEM1 (Promega Biotec, Madison, WI, USA). These pBR322 "backbone" sections are combined with an appropriate promoter and the structural sequence to be expressed.
  • the selected promoter is induced by appropriate means (e.g., temperature shift or chemical induction) and cells are cultured for an additional period.
  • appropriate means e.g., temperature shift or chemical induction
  • Cells are typically harvested by centrifugation, disrupted by physical or chemical means, and the resulting crude extract retained for further purification.
  • Microbial cells employed in expression of proteins can be disrupted by any convenient method, including freeze-thaw cycling, sonication, mechanical disruption, or use of cell lysing agents, such methods are well know to those skilled in the art.
  • Various mammalian cell culture systems can also be employed to express recombinant protein. Examples of mammalian expression systems include the COS-7 lines of monkey kidney fibroblasts, described by Gluzman, Cell, 23:175 (1981), and other cell lines capable of expressing a compatible vector, for example, the C127, 3T3, CHO, HeLa and BHK cell lines.
  • Mammalian expression vectors will comprise an origin of replication, a suitable promoter and enhancer, and also any necessary ribosome binding sites, polyadenylation site, splice donor and acceptor sites, transcriptional termination sequences, and 5' flanking nontranscribed sequences.
  • DNA sequences derived from the SV40 splice, and polyadenylation sites may be used to provide the required nontranscribed genetic elements.
  • the polypeptide can be recovered and purified from recombinant cell cultures by methods including ammonium sulfate or ethanol precipitation, acid extraction, anion or cation exchange chromatography, phosphocellulose chromatography, hydrophobic interaction chromatography, affinity chromatography hydroxylapatite chromatography and lectin chromatography. Protein refolding steps can be used, as necessary, in completing configuration of the mature protein. Finally, high performance liquid chromatography (HPLC) can be employed for final purification steps.
  • HPLC high performance liquid chromatography
  • polypeptides of the present invention may be a naturally purified product, or a product of chemical synthetic procedures, or produced by recombinant techniques from a prokaryotic or eukaryotic host (for example, by bacterial, yeast, higher plant, insect and mammalian cells in culture). Depending upon the host employed in a recombinant production procedure, the polypeptides of the present invention may be glycosylated or may be non-glycosylated. Polypeptides of the invention may also include an initial methionine amino acid residue.
  • the polypeptide of the present invention is also useful for identifying other molecules which may have similar biological activity.
  • Labeled oligonucleotides having a sequence complementary to that of the gene of the present invention are used to screen a library of human cDNA, genomic DNA or mRNA to determine which members of the library the probe hybridizes to.
  • polypeptides may also be employed in accordance with the present invention by expression of such polypeptides in vivo, which is often referred to as "gene therapy.”
  • cells from a patient may be engineered with a polynucleotide (DNA or RNA) encoding a polypeptide ex vivo, with the engineered cells then being provided to a patient to be treated with the polypeptide.
  • DNA or RNA polynucleotide
  • cells may be engineered by procedures known in the art by use of a retroviral particle containing RNA encoding a polypeptide of the present invention.
  • cells may be engineered in vivo for expression of a polypeptide in vivo by, for example, procedures known in the art.
  • a producer cell for producing a retroviral particle containing RNA encoding the polypeptide of the present invention may be administered to a patient for engineering cells in vivo and expression of the polypeptide in vivo.
  • the expression vehicle for engineering cells may be other than a retrovirus, for example, an adenovirus which may be used to engineer cells in vivo after combination with a suitable delivery vehicle.
  • a method for the treatment of a patient having need to modulate P2x receptor activity comprising administering a therapeutically effective amount of the polypeptide of the invention, for example by providing to the patient DNA encoding said polypeptide and expressing said polypeptide in vivo.
  • sequences of the present invention are also valuable for chromosome identification.
  • the sequence is specifically targeted to and can hybridize with a particular location on an individual human chromosome.
  • Few chromosome marking reagents based on actual sequence data (repeat polymorphisms) are presently available for marking chromosomal location.
  • the mapping of DNAs to chromosomes according to the present invention is an important first step in correlating those sequences with genes associated with disease. Briefly, sequences can be mapped to chromosomes by preparing PCR primers
  • PCR mapping of somatic cell hybrids is a rapid procedure for assigning a particular DNA to a particular chromosome.
  • sublocalization can be achieved with panels of fragments from specific chromosomes or pools of large genomic clones in an analogous manner.
  • Other mapping strategies that can similarly be used to map to its chromosome include in situ hybridization, prescreening with labeled flow-sorted chromosomes and preselection by hybridization to construct chromosome specific-cDNA libraries.
  • Fluorescence in situ hybridization (FISH) of a cDNA clones to a metaphase chromosomal spread can be used to provide a precise chromosomal location in one step.
  • This technique can be used with cDNA as short as 500 or 600 bases; however, clones larger than 2,000 bp have a higher likelihood of binding to a unique chromosomal l l location with sufficient signal intensity for simple detection.
  • FISH requires use of the clones from which the EST was derived, and the longer the better. For example, 2,000 bp is good, 4,000 is better, and more than 4,000 is probably not necessary to get good results a reasonable percentage of the time.
  • Verma et al. Human Chromosomes: a Manual of Basic Techniques, Pergamon Press, New York (1988).
  • a cDNA precisely localized to a chromosomal region associated with the disease could be one of between 50 and 500 potential causative genes. (This assumes 1 megabase mapping resolution and one gene per 20 kb).
  • Comparison of affected and unaffected individuals generally involves first looking for structural alterations in the chromosomes, such as deletions or translocations that are visible from chromosome spreads or detectable using PCR based on that cDNA sequence. Ultimately, complete sequencing of genes from several individuals is required to confirm the presence of a mutation and to distinguish mutations from polymorphisms.
  • the polypeptides, their fragments or other derivatives, or analogs thereof, or cells expressing them can be used as an immunogen to produce antibodies thereto. These antibodies can be, for example, polyclonal or monoclonal antibodies.
  • the present invention also includes chimeric, single chain, and humanized antibodies, as well as Fab fragments, or the product of an Fab expression library. Various procedures known in the art may be used for the production of such antibodies and fragments.
  • Antibodies generated against the polypeptides corresponding to a sequence of the present invention can be obtained by direct injection of the polypeptides into an animal or by administering the polypeptides to an animal, preferably a nonhuman. The antibody so obtained will then bind the polypeptides itself. In this manner, even a sequence encoding only a fragment of the polypeptides can be used to generate antibodies binding the whole native polypeptides. Such antibodies can then be used to isolate the polypeptide from tissue expressing that polypeptide.
  • any technique which provides antibodies produced by continuous cell line cultures can be used. Examples include the hybridoma technique (Kohler and Milstein, 1975, Nature, 256:495-497), the trioma technique, the human B-cell hybridoma technique (Kozbor et al., 1983, Immunology Today 4:72), and the EBV-hybridoma technique to produce human monoclonal antibodies (Cole, et al., 1985, in Monoclonal Antibodies and Cancer Therapy, Alan R. Liss, Inc., pp. 77-96).
  • This invention provides a method of screening drugs to identify those which block (antagonists) functional interaction of ligand with the human brain P2x receptor of the invention, the method comprising measuring the ability of test compound to block interaction of ligand (usually ATP or a stable analogue thereof) with the receptor.
  • ligand usually ATP or a stable analogue thereof
  • a mammalian cell or membrane preparation expressing the P2x receptor would be incubated with labeled ligand in the presence of the drug. The ability of the drug to block this interaction could then be measured.
  • an assay combines an appropriate ligand labelled with radio-activity, eg., [35s]-dATP ⁇ S, and a potential antagonist/inhibitor with membrane-bound P2 ⁇ receptors or recombinant forms of the P2 X receptor under appropriate conditions for a competitive inhibition assay, such that the number of radiolabelled molecules bound to the receptor can determine the effectiveness of the potential antagonist/inhibitor.
  • a known second (or third) messenger system following interaction of ligand and receptor would be measured compared in the presence or absence of the drug.
  • messenger systems include but are not limited to, cAMP guanylate cyclase, ion channels or phosphoinositide hydrolysis. They may also include the measurement of extracellular pH as an index of overall cell function.
  • This invention also provides transgenic non-human animals comprising a polynucleotide encoding a polypeptide of the invention. Also provided are methods for use of said transgenic animals as models for mutation and SAR (structure/activity relationship) evaluation as well as in drug screens.
  • the present invention is also directed to antagonist/inhibitor molecules of the polypeptides of the present invention, and their use in reducing or eliminating the function of the polypeptide.
  • the invention further provides a method for the treatment of a patient having need to reduce or eliminate the function of the polypeptide comprising: administering to the patient a therapeutically effective amount of the antagonist/inhibitor of the invention.
  • an antagonist is an antibody or in some cases, an oligonucleotide which binds to the polypeptide.
  • the antagonists may be closely related proteins such that they recognize and bind to the receptor sites of the natural protein, however, they are inactive forms of the polypeptide and thereby prevent the action of ATP since receptor sites are occupied.
  • an inhibitor is an antisense constructs prepared using antisense technology.
  • Antisense technology can be used to control gene expression through triple- helix formation or antisense DNA or RNA, both of which methods are based on binding of a polynucleotide to DNA or RNA.
  • the 5' coding portion of the polynucleotide sequence which encodes for the mature polypeptides of the present invention, is used to design an antisense RNA oligonucleotide of from about 10 to 40 base pairs in length.
  • a DNA oligonucleotide is designed to be complementary to a region of the gene involved in transcription (triple helix -see Lee et al., Nucl.
  • the antisense RNA oligonucleotide hybridizes to the mRNA in vivo and blocks translation of the mRNA molecule into the P2 X receptor (antisense - Okano, J. Neurochem., 56:560 (1991); Oligodeoxynucleotides as Antisense Inhibitors of Gene Expression, CRC Press, Boca Raton, FL (1988)).
  • the oligonucleotides described above can also be delivered to cells such that the antisense RNA or DNA may be expressed in vivo to inhibit production of the P2 ⁇ receptor.
  • an antagonist/inhibitor is a small molecule which binds to and occupies the receptor binding site, thereby making the site inaccessible to its natural ligand or which binds to a related site which affects the function of ATP in an allosteric manner such that normal biological activity is prevented.
  • small molecules include but are not limited to small peptides or peptide-like molecules.
  • the antagonist/inhibitors may be employed to treat conditions associated with an inappropriately high presence of ATP. These include conditions in which there is an excessive release of ATP from hyperactive neurones that normally contain ATP as a neurotransmitter. They may also include conditions in which ATP is released from damaged cells, to affect the surrounding neurones.
  • These actions may include the mimicry of fast synaptic events and the induction of apoptosis or of cell necrosis, based on the know ability of ATP to induce apoptosis and cell death (Zheng et al., 1991, J Cell Biol., 112, 279-288) and on the high sequence homology between at least one type of rat P2x receptor (Valera et al, 1994 above) and the apoptotic gene product RP-2, expressed by rat thymocytes during apoptosis (Owens et al., 1991, Mol Cell Biol., 11, 4177-4188).
  • Localisation of the P2 ⁇ - 1 receptor and / or the P2 ⁇ -2 receptor within the various regions of the brain means that therapeutic agents which modulate the activity of these receptors will be indicated for a number of important clinical conditions, including brain stroke, brain or spinal cord traumas, infection and inflammation, cognitive disorders, epilepsy, affective and mood disorders in general, including depression, various movement disorders including Parkinson's disease, Huntingtons Chorea and schizophrenia, as well as those conditions that are associated with the development of chronic or acute forms of pain.
  • variable distribution of the P2 ⁇ receptors of the invention suggests that the clinical indication of drugs which affect a particular splice variant of the P2 X receptor will depend on its exact location within the brain.
  • the P2 X receptors of the invention are also present in certain tissues outside the brain, such as the heart and liver, where they will play a role in various conditions associated with tissue damage - eg., cardiac anoxia.
  • compositions which form part of the invention, comprise a therapeutically or prophylactically effective amount of the active substance, and a pharmaceutically acceptable carrier or excipient.
  • a carrier includes but is not limited to saline, buffered saline, dextrose, water, glycerol, ethanol, and combinations thereof. The formulation should suit the mode of administration.
  • the invention also provides a pharmaceutical pack or kit comprising one or more containers filled with one or more of the ingredients of the pharmaceutical compositions of the invention.
  • a pharmaceutical pack or kit comprising one or more containers filled with one or more of the ingredients of the pharmaceutical compositions of the invention.
  • Associated with such container(s) can be a notice in the form prescribed by a governmental agency regulating the manufacture, use or sale of pharmaceuticals or biological products, which notice reflects approval by the agency of manufacture, use or sale for human administration.
  • the active substances of the present invention may be employed in conjunction with other therapeutic compounds.
  • the pharmaceutical compositions may be administered in a convenient manner such as by the oral, topical, intravenous, intraperitoneal, intramuscular, subcutaneous, intranasal or intradermal routes.
  • the active substance is administered in an amount which is effective for treating and/or prophylaxis of the specific indication.
  • the amounts and dosage regimens of active substance and administered to a subject will depend on a number of factors such as the mode of administration, the nature of the condition being treated and the judgment of the prescribing physician.
  • the active substance will be administered in an amount of at least about x mg/kg body weight and in most cases they will be administered in an amount not in excess of about y mg/kg body weight per day, taking into account the routes of administration, symptoms, etc.
  • Plasmids are designated by a lower case p preceded and/or followed by capital letters and/or numbers.
  • the starting plasmids herein are either commercially available, publicly available on an unrestricted basis, or can be constructed from available plasmids in accord with published procedures.
  • equivalent plasmids to those described are known in the art and will be apparent to the ordinarily skilled artisan.
  • “Digestion” of DNA refers to catalytic cleavage of the DNA with a restriction enzyme that acts only at certain sequences in the DNA.
  • the various restriction enzymes used herein are commercially available and their reaction conditions, cofactors and other requirements were used as would be known to the ordinarily skilled artisan.
  • For analytical purposes typically 1 ⁇ g of plasmid or DNA fragment is used with about 2 units of enzyme in about 20 ⁇ l of buffer solution.
  • For the purpose of isolating DNA fragments for plasmid construction typically 5 to 50 ⁇ g of DNA are digested with 20 to 250 units of enzyme in a larger volume. Appropriate buffers and substrate amounts for particular restriction enzymes are specified by the manufacturer. Incubation times of about 1 hour at 37 C are ordinarily used, but may vary in accordance with the supplier's instructions. After digestion the reaction is electrophoresed directly on a polyacrylamide gel to isolate the desired fragment.
  • Oligonucleotides refers to either a single stranded polydeoxynucleotide or two complementary polydeoxynucleotide strands which may be chemically synthesized. Such synthetic oligonucleotides have no 5' phosphate and thus will not ligate to another oligonucleotide without adding a phosphate with an ATP in the presence of a kinase. A synthetic oligonucleotide will ligate to a fragment that has not been dephosphorylated.
  • Ligase refers to the process of forming phosphodiester bonds between two double stranded nucleic acid fragments (Maniatis, T., et al., Id., p. 146). Unless otherwise provided, ligation may be accomplished using known buffers and conditions with 10 units to T4 DNA ligase ("ligase”) per 0.5 ⁇ g of approximately equimolar amounts of the DNA fragments to be ligated.
  • ligase T4 DNA ligase
  • Partial cDNA was obtained from a human brain frontal cortex (taken from a schizophrenia patient) cDNA library. A comparison of the sequence with the published rat P2 ⁇ receptors, referred to above, suggested that this EST sequence was approximately 300bp short of a full length cDNA sequence.
  • Marathon-Ready cDNA (Clonetech Laboratories, Inc., 4030 Fabian way, Palo Alto, CA 94303-40607 USA) sythesised from adult human frontal cortex RNA was obtained and standard RACE technology used as described in methods outlined in the Marathon-Ready cDNA Kit (cat. #PT1156-1).
  • RACE was performed using a 5' oligonucleotide (API 5'- CCA TCC TAA TAC GAC TCA CTA TAG GGC-3') which was supplied in Marathon- Ready kit and a 3' oligonuclotide (#1, 5'- ACA CAC AGT GGT CGC ATC TGG AAT C- 3') complimentary to the 5' end of the partial cDNA sequence.
  • API 5'- CCA TCC TAA TAC GAC TCA CTA TAG GGC-3' was supplied in Marathon- Ready kit and a 3' oligonuclotide (#1, 5'- ACA CAC AGT GGT CGC ATC TGG AAT C- 3') complimentary to the 5' end of the partial cDNA sequence.
  • Marathon-Ready cDNA (20ng) were amplified by following standard PCR protocols and using Taq DNA polymerase (Applied Biosystems, Warrington UK) in a touch down PCR described in Don et al 1991 (Nucleic Acid Research Vol 19, 4008).
  • the initial annealing temperature for touch down PCR started at 60°C and was reduced by 1°C every 1 cycle for 10 cycles (final annealing temperature 50°C) where it was then cycled for 20 more cycles. Each cycle also contained polymerisation (72°C, 1 min) and denaturation (94°C 1 min) steps and the PCR finished off with a final 10 min 72°C polishing step.
  • First strand sequence was obtained using AP2 (5'-ACT CAC TAT AGG GCT CGA GCG GC-3'; Clontech) and SP6 primers purchased from BRL. After determination of first strand sequence a set of oligonucleotide primers #8 (5'-CCT TCC TGT TCG AGT ACG AC-3') and #9 ( 5'-TCC CAG ATC CGG AAT CCA AG-3' ) were synthesised and used to obtain the remainder of the sequence of P2X-1 (SEQ ID NO 1) P2X-2 (SEQ ID NO 2) Example 2 PCR localization
  • Poly A + mRNA was purchased from Clonetech or isolated from normal human brain tissues using Trizol (methods supplied by BRL). Human genomic DNA was purchased from Promega.
  • the hybridization was performed with standard protocols as in Snutch et al 1991 (Neuron, Vol 7, 45-57) with a final wash temperature of 60°C in 0.5x SSC. Southern blots were then exposed directly to X-Omat R film for 72 hours. The film was developed and images were examined on an optimas imaging system.
  • the primers used in the PCR reaction — oligo 8 and oligo 9 - were designed to amplify across the splice site in P2 X - 1 and P2 ⁇ -2.
  • RT-PCR with these primers on poly A+ RNA from human brain regions produced two products of 226bp and 274bp representing both P isoforms respectively.
  • the 226bp ( Figure 6) product represents P2 X -1 and was amplified from total brain, amygdala, caudate, cerebellum, hippocampus, substantia nigra, thalamus, spinal cord and heart mRNAs.
  • Tissue sections were exposed directly to X-Omat R film for 10 days. The film was developed and images were examined on an optimas imaging system. Slides were dipped in photographic emulsion (Kodak) and exposed for a further 6 weeks.
  • Kodak photographic emulsion
  • ATG is at nucleotide 14.
  • the 48bp insertion begins at nucleotide 135.
  • Gen Genomic DNA SN: Substantia Nigra Li: Liver Hi: Hippocampus He: Heart C: Cerebellum SC: Spinal cord Ca: Caudate FC: Frontal cortex A: Amygdala Hy: Hypothalamus B: Whole Brain Th: Thalamus
  • Gen Genomic DNA SN: Substantia Nigra Li: Liver Hi: Hippocampus He: Heart C: Cerebellum SC: Spinal cord Ca: Caudate FC: Frontal cortex A: Amygdala Hy: Hypothalamus B: Whole Brain Th: Thalamus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Psychology (AREA)
  • Biochemistry (AREA)
  • Pain & Pain Management (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Hospice & Palliative Care (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Food Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)

Abstract

L'invention concerne des séquences de polynucléotides codant pour des allèles d'épissage du récepteur cérébral P2x4 humain. Elle concerne également l'expression recombinante desdits récepteurs et leur utilisation pour cribler des antagonistes.
PCT/GB1996/001034 1996-04-30 1996-04-30 ALLELES D'EPISSAGE DU RECEPTEUR P2x4 HUMAIN WO1997041222A1 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
JP53864697A JP2001521372A (ja) 1996-04-30 1996-04-30 ヒトＰ２ｘ４レセプタースプライス−変異体
AU55068/96A AU5506896A (en) 1996-04-30 1996-04-30 Human p2x4 receptor splice-variants
PCT/GB1996/001034 WO1997041222A1 (fr) 1996-04-30 1996-04-30 ALLELES D'EPISSAGE DU RECEPTEUR P2x4 HUMAIN
EP96912122A EP0907729A1 (fr) 1996-04-30 1996-04-30 ALLELES D'EPISSAGE DU RECEPTEUR P2x4 HUMAIN

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/GB1996/001034 WO1997041222A1 (fr) 1996-04-30 1996-04-30 ALLELES D'EPISSAGE DU RECEPTEUR P2x4 HUMAIN

Publications (1)

Publication Number Publication Date
WO1997041222A1 true WO1997041222A1 (fr) 1997-11-06

Family

ID=10787223

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB1996/001034 WO1997041222A1 (fr) 1996-04-30 1996-04-30 ALLELES D'EPISSAGE DU RECEPTEUR P2x4 HUMAIN

Country Status (4)

Country Link
EP (1) EP0907729A1 (fr)
JP (1) JP2001521372A (fr)
AU (1) AU5506896A (fr)
WO (1) WO1997041222A1 (fr)

Cited By (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998018916A1 (fr) * 1996-10-30 1998-05-07 Incyte Pharmaceuticals, Inc. Purino-recepteur p2x humain
WO1999055901A2 (fr) * 1998-04-30 1999-11-04 Abbott Laboratories Technique de criblage fonctionnel de grande capacite servant a identifier des ligands de purinorecepteurs humains
WO2001006259A1 (fr) 1999-04-21 2001-01-25 Biosceptre Pty Ltd Procede d'identification d'etats preneoplasiques et neoplasiques chez des mammiferes
US6242216B1 (en) 1997-11-14 2001-06-05 Abbott Laboratories Nucleic acids encoding a functional human purinoreceptor P2X2 and P2X4, and methods of production and use thereof
EP1470145A2 (fr) * 2001-12-31 2004-10-27 Algos Therapeutics, Inc. Methodes et materiels destines a la modulation de p2x2
WO2006130676A2 (fr) * 2005-05-31 2006-12-07 Duska Scientific Co. Inhibition de dommages neuronaux
WO2007042776A1 (fr) * 2005-10-07 2007-04-19 Imperial College Innovations Limited Modulateurs de la voie de signalisation purinergique pour traiter l'homeostasie du sodium, l'hypertension et l'hyperaldosteronisme
US7531171B2 (en) 2001-01-17 2009-05-12 Intreat Pty Limited Antibodies to non-functional P2X7 receptor
US8067550B2 (en) 2006-10-10 2011-11-29 Biosceptre International Limited Hybridomas producing antibodies against non functional P2X7 receptor
US8440186B2 (en) 2007-09-14 2013-05-14 Biosceptre International Limited P2X7 epitopes
US8597643B2 (en) 2008-07-04 2013-12-03 Biosceptre International Limited Antibodies for binding to non-functional P2X7 receptors in trimeric form
US8658385B2 (en) 2007-09-14 2014-02-25 Biosceptre International Limited Purinergic (P2X) receptors in extra-cellular body fluid
US8835609B2 (en) 2009-12-24 2014-09-16 Biosceptre International Limited Antigen binding sites to non-functional oligomeric P2X7 receptors and methods of use thereof
US9127059B2 (en) 2009-08-20 2015-09-08 Biosceptre International Limited Anti P2X7 receptor antibodies and fragments thereof
US9562094B2 (en) 2010-09-10 2017-02-07 Biosceptre (Aust) Pty Ltd Companion animal treatments
US9566318B2 (en) 2011-07-01 2017-02-14 Biosceptre (Aust) Pty Ltd Combination therapy
US12129295B2 (en) 2009-08-20 2024-10-29 Biosceptre (Aust) Pty Ltd Anti P2X7 receptor antibodies and fragments thereof

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2010002683A (es) * 2007-09-14 2010-03-26 Amgen Inc Poblaciones de anticuerpos homogeneos.

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995033048A2 (fr) * 1994-05-27 1995-12-07 Glaxo Group Limited Recepteurs p2x (famille des purinorecepteurs)

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995033048A2 (fr) * 1994-05-27 1995-12-07 Glaxo Group Limited Recepteurs p2x (famille des purinorecepteurs)

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
SEGUELA ET AL.: "A novel neuronal P2x ATP receptor ion channel with widespread distribution in the brain", THE JOURNAL OF NEUROSCIENCE, vol. 16, no. 2, 15 January 1996 (1996-01-15), pages 448 - 455, XP000616491 *
WANG ET AL.: "Cloning and pharmacological characterization of a fourth P2x receptor subtype widely expressed in brain and peripheral tissues including various endocrine tissues", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 220, no. 1, 7 March 1996 (1996-03-07), pages 196 - 202, XP002023836 *

Cited By (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5856129A (en) * 1996-10-30 1999-01-05 Incyte Pharmaceuticals, Inc. DNA encoding a human purinoceptor
WO1998018916A1 (fr) * 1996-10-30 1998-05-07 Incyte Pharmaceuticals, Inc. Purino-recepteur p2x humain
US6242216B1 (en) 1997-11-14 2001-06-05 Abbott Laboratories Nucleic acids encoding a functional human purinoreceptor P2X2 and P2X4, and methods of production and use thereof
WO1999055901A2 (fr) * 1998-04-30 1999-11-04 Abbott Laboratories Technique de criblage fonctionnel de grande capacite servant a identifier des ligands de purinorecepteurs humains
WO1999055901A3 (fr) * 1998-04-30 2000-04-20 Abbott Lab Technique de criblage fonctionnel de grande capacite servant a identifier des ligands de purinorecepteurs humains
US7183064B1 (en) 1999-04-21 2007-02-27 Biosceptre Pty Ltd Method for identifying pre-neoplastic and/or neoplastic states in mammals
WO2001006259A1 (fr) 1999-04-21 2001-01-25 Biosceptre Pty Ltd Procede d'identification d'etats preneoplasiques et neoplasiques chez des mammiferes
EP1179183A1 (fr) * 1999-04-21 2002-02-13 Biosceptre Pty Ltd Procede d'identification d'etats preneoplasiques et neoplasiques chez des mammiferes
EP1179183A4 (fr) * 1999-04-21 2003-01-22 Biosceptre Pty Ltd Procede d'identification d'etats preneoplasiques et neoplasiques chez des mammiferes
US7531171B2 (en) 2001-01-17 2009-05-12 Intreat Pty Limited Antibodies to non-functional P2X7 receptor
US10450380B2 (en) 2001-01-17 2019-10-22 Biosceptre (Aust) Pty Ltd Polypeptide immunogen for generating an antibody to non-functional P2X7 receptor
US9663584B2 (en) 2001-01-17 2017-05-30 Biosceptre (Aust) Pty Ltd Antibodies to non-functional P2X7 receptor
US7888473B2 (en) 2001-01-17 2011-02-15 Intreat Pty Limited Non-functional P2X7 receptor
US8709425B2 (en) 2001-01-17 2014-04-29 Biosceptre International Limited Antibodies to non-functional P2X7 receptor
US8080635B2 (en) 2001-01-17 2011-12-20 Biosceptre International Limited Non-functional P2X7 receptor
US8399617B2 (en) 2001-01-17 2013-03-19 Biosceptre International Limited Non-functional P2X7 receptor
EP1470145A4 (fr) * 2001-12-31 2005-05-25 Algos Therapeutics Inc Methodes et materiels destines a la modulation de p2x2
EP1470145A2 (fr) * 2001-12-31 2004-10-27 Algos Therapeutics, Inc. Methodes et materiels destines a la modulation de p2x2
WO2006130676A2 (fr) * 2005-05-31 2006-12-07 Duska Scientific Co. Inhibition de dommages neuronaux
WO2006130676A3 (fr) * 2005-05-31 2007-08-02 Duska Scient Co Inhibition de dommages neuronaux
EP2305258A3 (fr) * 2005-05-31 2011-07-06 Duska Scientific Co Prevention des lesions neuronales
GB2446735A (en) * 2005-10-07 2008-08-20 Imp College Innovations Ltd Modulators of the purinergic signalling pathway for treating sodium homeostatis hypertension and aldosteronism
WO2007042776A1 (fr) * 2005-10-07 2007-04-19 Imperial College Innovations Limited Modulateurs de la voie de signalisation purinergique pour traiter l'homeostasie du sodium, l'hypertension et l'hyperaldosteronisme
US8067550B2 (en) 2006-10-10 2011-11-29 Biosceptre International Limited Hybridomas producing antibodies against non functional P2X7 receptor
US8440186B2 (en) 2007-09-14 2013-05-14 Biosceptre International Limited P2X7 epitopes
US8658385B2 (en) 2007-09-14 2014-02-25 Biosceptre International Limited Purinergic (P2X) receptors in extra-cellular body fluid
US10597451B2 (en) 2007-09-14 2020-03-24 Biosceptre (Aust) Pty Ltd Methods of treating cancer with a P2X7 peptide
US9181320B2 (en) 2007-09-14 2015-11-10 Biosceptre International Limited Peptides for generating an antibody selectively binding to a non-ATP-binding P2X7 receptor but not to an ATP-binding P2X7 receptor
US9944701B2 (en) 2007-09-14 2018-04-17 Biosceptre (Aust) Pty Ltd Methods of treating cancer with antibodies that bind P2X7 receptors
US8597643B2 (en) 2008-07-04 2013-12-03 Biosceptre International Limited Antibodies for binding to non-functional P2X7 receptors in trimeric form
US9328155B2 (en) 2008-07-04 2016-05-03 Biosceptre (Aust) Pty Ltd Peptides for inducing antibodies to a non-functional P2X7 receptor
US10238716B2 (en) 2008-07-04 2019-03-26 Biosceptre (Aust) Pty Ltd Anti-P2X7 peptides and epitopes
US9127059B2 (en) 2009-08-20 2015-09-08 Biosceptre International Limited Anti P2X7 receptor antibodies and fragments thereof
US9688771B2 (en) 2009-08-20 2017-06-27 Biosceptre (Aust) Pty Ltd Anti P2X7 receptor antibodies and fragments thereof
US10053508B2 (en) 2009-08-20 2018-08-21 Biosceptre (Aust) Pty Ltd Anti P2X7 receptor antibodies and fragments thereof
US10988532B2 (en) 2009-08-20 2021-04-27 Biosceptre (Aust) Pty Ltd Anti P2X7 receptor antibodies and fragments thereof
US12129295B2 (en) 2009-08-20 2024-10-29 Biosceptre (Aust) Pty Ltd Anti P2X7 receptor antibodies and fragments thereof
US9428587B2 (en) 2009-12-24 2016-08-30 Biosceptre International Limited Antibodies to non-functional oligomeric P2X7 receptors and methods of use thereof
US8835609B2 (en) 2009-12-24 2014-09-16 Biosceptre International Limited Antigen binding sites to non-functional oligomeric P2X7 receptors and methods of use thereof
US10232025B2 (en) 2010-09-10 2019-03-19 Biosceptre (Ausi) Pty Ltd Method for minimising progression of cancer in companion animals
US9562094B2 (en) 2010-09-10 2017-02-07 Biosceptre (Aust) Pty Ltd Companion animal treatments
US9566318B2 (en) 2011-07-01 2017-02-14 Biosceptre (Aust) Pty Ltd Combination therapy
US10245308B2 (en) 2011-07-01 2019-04-02 Biosceptre (Aust) Pty Ltd Combination therapy utilizing P2X7 peptides
US10543262B2 (en) 2011-07-01 2020-01-28 Biosceptre (Aust) Pty Ltd Combination therapy utilizing P2X7 peptides

Also Published As

Publication number Publication date
JP2001521372A (ja) 2001-11-06
AU5506896A (en) 1997-11-19
EP0907729A1 (fr) 1999-04-14

Similar Documents

Publication Publication Date Title
WO1997041222A1 (fr) ALLELES D'EPISSAGE DU RECEPTEUR P2x4 HUMAIN
JP2010047588A (ja) 新規膜貫通蛋白質をコードする遺伝子
US20030027164A1 (en) Novel human nucleic acid molecules and polypeptides encoding a novel human ion channel expressed in spinal cord and brain
JPH11225774A (ja) 免疫グロブリン遺伝子スーパーファミリーのメンバー、ｐｉｇｒ−１
US6639052B1 (en) Human ADA2 polypeptides
EP0854191A2 (fr) Protéine humaine du type cardiac/cerveau-tolloid
WO1997044454A2 (fr) Inhibiteur de la phospholipase chez l'homme
US6358702B1 (en) Polynucleotides encoding human Hox C10
US20020106740A1 (en) Human G-protein receptor HPRAJ70
US5747312A (en) Human AlkB polypeptide
JP2003210183A (ja) ヒトＩκＢ−β
EP0910641A1 (fr) Variantes d'epissage de molecule d'adherence cellulaire neuronale
EP0894856A1 (fr) Variante d'épissure de sMAD3 humaine
JPH11206391A (ja) ヒトｌｉｇ−１相同体（ｈｌｉｇ−１）
US6630443B2 (en) Human amine transporter antibodies
JP2000083683A (ja) Ｆｒｚｂファミリ―のメンバ―、ｆｒａｚｚｌｅｄ
WO1999021885A1 (fr) Gene transporteur 7 abc humain (habc7)
EP0879886A2 (fr) HLDAT86, Protéine de la transduction de signaux et homoloque humaine de Wnt-4
US20020119487A1 (en) Human stem cell antigen 2
US20040034210A1 (en) Novel polypeptide-protein p125-77.22 and a polynucleotide encoding the same
WO1999021982A1 (fr) Gene m6b1 humain
EP0788540A1 (fr) Abh humain
JP2002223778A (ja) 慢性腎不全の標的およびマーカーであるｃｒｆｇ−１
CA2230866A1 (fr) Alleles d'epissage du recepteur p2x4 humain
US20040248091A1 (en) Novel polypeptide-human g-protein and the polynucleotide encoding the same

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AL AM AT AU AZ BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IS JP KE KG KP KR KZ LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG US UZ VN AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref document number: 2230866

Country of ref document: CA

Ref country code: CA

Ref document number: 2230866

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 1996912122

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1996912122

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1996912122

Country of ref document: EP